诺诚健华(09969)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09969 诺诚健华

休市中 08-14 16:08:36

14.940

-0.040

-0.27%

最高15.180	最低14.540	成交量454.40万
今开15.000	昨收14.980	日振幅4.27%
总市值263.99亿	流通市值223.20亿	总股本17.67亿
成交额6,755万	换手率0.30%	流通股本14.94亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09969","market":"HK","secType":"STK","nameCN":"诺诚健华","latestPrice":14.94,"timestamp":1786694916009,"preClose":14.98,"halted":0,"volume":4544000,"delay":0,"changeRate":-0.0026702269692924514,"floatShares":1494000000,"shares":1767000000,"eps":0.38,"marketStatus":"休市中","change":-0.04,"latestTime":"08-14 16:08:36","open":15,"high":15.18,"low":14.54,"amount":67554145,"amplitude":0.042724,"askPrice":14.94,"askSize":12000,"bidPrice":14.93,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":0.469,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1786930200000},"marketStatusCode":7,"adr":0,"listingDate":1584892800000,"exchange":"SEHK","adjPreClose":14.98,"openAndCloseTimeList":[[1786671000000,1786680000000],[1786683600000,1786694400000]],"volumeRatio":0.41976529947061275,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688428","market":"SH","secType":"STK","nameCN":"诺诚健华","latestPrice":31.92,"timestamp":1786690800000,"preClose":31.8,"halted":0,"volume":12219900,"delay":0,"premium":"-59.77"}},"requestUrl":"/m/hq/s/09969","defaultTab":"news","newsList":[{"id":"2659175044","title":"每周股票复盘：诺诚健华（688428）将公布2026年中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2659175044","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659175044?lang=zh_cn&edition=full","pubTime":"2026-08-16 02:24","pubTimestamp":1786818253,"startTime":"0","endTime":"0","summary":"截至2026年8月14日收盘，诺诚健华报收于31.92元，较上周的29.08元上涨9.77%。本周，诺诚健华8月13日盘中最高价报33.33元。8月11日盘中最低价报28.67元。诺诚健华当前最新总市值564.7亿元，在化学制药板块市值排名8/149，在两市A股市值排名364/5207。本周关注点公司公告汇总：诺诚健华将于2026年8月24日召开董事会，审议发布截至2026年6月30日止六个月的中期业绩。公告日期为2026年8月11日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081600000560.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK1574","BK0239","09969","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658916916","title":"诺诚健华（688428）披露董事会将于8月24日审议2026年中期业绩，8月11日股价上涨6.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658916916","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658916916?lang=zh_cn&edition=full","pubTime":"2026-08-11 22:05","pubTimestamp":1786457109,"startTime":"0","endTime":"0","summary":"截至2026年8月11日收盘，诺诚健华报收于31.4元，较前一交易日上涨6.95%，最新总市值为555.5亿元。该股当日开盘29.45元，最高32.5元，最低28.67元，成交额达7.94亿元，换手率为9.42%。近日，诺诚健华医药有限公司发布公告称，董事会将于2026年8月24日举行会议，考虑并批准公司及其附属公司截至2026年6月30日止六个月中期业绩的发布。公告日期为2026年8月11日。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081100037842.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688428","09969","BK1574","BK1161","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658177995","title":"诺诚健华：截止到2026年7月31日公司A股股东户数约为1.8万户","url":"https://stock-news.laohu8.com/highlight/detail?id=2658177995","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658177995?lang=zh_cn&edition=full","pubTime":"2026-08-11 17:03","pubTimestamp":1786439001,"startTime":"0","endTime":"0","summary":"证券之星消息，诺诚健华(688428)08月11日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截止到7月31日公司股东人数是多少？谢谢诺诚健华回复：尊敬的投资者，您好！截止到2026年7月31日公司A股股东户数约为1.8万户。感谢您的关注！本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081100026868.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK1161","688428","BK0239","159982","399300","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151325182","title":"诺诚健华医药（09969）将于2026年8月24日召开董事会审议中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1151325182","media":"公告速递","labels":["conferences","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1151325182?lang=zh_cn&edition=full","pubTime":"2026-08-11 17:01","pubTimestamp":1786438879,"startTime":"0","endTime":"0","summary":"诺诚健华医药有限公司（09969）8月11日在港交所公告称，公司董事会会议将于2026年8月24日举行，届时将审议并批准公司及其附属公司截至2026年6月30日止六个月的中期业绩及其发布事宜。\n根据公告，董事会成员包括主席兼执行董事崔霽松博士、执行董事赵仁滨博士、非执行董事施一公博士及谢榕刚先生，以及独立非执行董事胡兰女士、董丹丹博士和管坤良教授。\n公司表示，将在董事会会议后及时披露中期业绩报告的相关信息。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658369969","title":"创新药概念继续走强 金斯瑞生物科技（01548）涨6.87% 机构指中国创新药全球地位持续提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2658369969","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658369969?lang=zh_cn&edition=full","pubTime":"2026-08-11 11:15","pubTimestamp":1786418137,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股创新药概念持续走强，截至发稿，金斯瑞生物科技 涨6.87%，再鼎医药涨5.51%，同源康医药-B涨4.81%，晶泰控股涨3.94%，药明合联涨3.92%，翰森制药涨3.76%，亚盛医药涨3.63%，百济神州涨3.38%，药明康德涨3.03%，诺诚健华涨2.83%，石药集团涨2.78%。国元国际证券亦表示，出海交易量价齐升，中国创新药全球地位持续提升。中国创新药出海持续超预期，上半年997亿美元的交易总额和全球TOP10中独占8席的成绩，充分验证了中国创新药资产的全球竞争力。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250110/MmQ2MzI0NzdkYTM0MjU4ODU0NDE5OWM2MjQ0NmE1ZTExMDg1Mjk2Mjc3MDg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/MmQ2MzI0NzdkYTM0MjU4ODU0NDE5OWM2MjQ0NmE1ZTExMDg1Mjk2Mjc3MDg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1987912","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2039709279.SGD","LU2488822045.USD","BK1521","LU0072913022.USD","LU1226288170.HKD","LU2242644610.SGD","LU1993786604.SGD","LU1152091168.USD","01093","03692","LNGR","LU0326950275.SGD","LU1226287792.SGD","LU0315179316.USD","06855","BK1588","BK1617","LU0880133367.SGD","HK0000320223.HKD","IE00B5MMRT66.SGD","09969","IBBQ","LU1813983027.USD","02410","06978","02268","BK1161","BK1515","LU1303224171.USD","LU1951186391.HKD","02228","06160","BK1583","159992","IE00BZ08YT58.USD","IE00B031HY20.USD","LU1226287875.USD","MEDX","IE00B543WZ88.USD","HK0000306685.HKD","LU2125910500.SGD","IE00BZ08YS42.EUR","09688","02359","IE00BZ08YR35.GBP","BK1576","LU2328871848.SGD","KURE","BK1500","01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116736257","title":"异动解读｜诺诚健华盘中上涨5.17%，自免管线多项临床里程碑兑现带动持续上行","url":"https://stock-news.laohu8.com/highlight/detail?id=1116736257","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1116736257?lang=zh_cn&edition=full","pubTime":"2026-08-10 10:07","pubTimestamp":1786327639,"startTime":"0","endTime":"0","summary":"8月10日，诺诚健华盘中上涨5.17%，报15.04港元，成交额5838.7万港元。多条自免管线集中读出积极数据，叠加公司A股上周累计上涨9.9%，港股延续补涨态势。同日生物科技板块整体走强，康方生物涨4.3%、荣昌生物涨4.7%、三生制药涨3.23%，行业情绪共振进一步推动个股上行。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658609667","title":"港股生物医药股盘初走高，药明康德股价突破200港元关口创历史新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2658609667","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658609667?lang=zh_cn&edition=full","pubTime":"2026-08-10 09:51","pubTimestamp":1786326707,"startTime":"0","endTime":"0","summary":"热点栏目自选股\n数据中心\n行情中心\n资金流向\n模拟交易客户端港股生物医药股盘初走高，药明康德一度涨超5%，股价突破200港元关口创历史新高，现涨超4%；再鼎医药涨超5%，诺诚建华、药明生物涨超3%。开源证券发布研报表示，投资上，我们建议重点关注减重代谢领域中口服司美格鲁肽及Foundayo两个确定性的增量机会。同时，药明康德小分子D&M 业务大体量下加速增长，预示着国内小分子CDMO 板块有望在未来3-5年迎来增长新周期，相关公司的签单收入有望逐步加速，利润端有望超预期增长。","market":"hk","thumbnail":"https://static.tigerbbs.com/25bb080e73b6be662c435ea6aeaec9c7","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/25bb080e73b6be662c435ea6aeaec9c7"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/2026-08-10/doc-inimuvrt8236475.shtml","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0611395673.USD","LU1808992512.USD","VXUS","XBI","LU1719994722.HKD","BK1583","LU2488822045.USD","02359","LU1303224171.USD","LU1934453819.USD","09688","LU0708995583.HKD","EWH","LU1046422090.SGD","LU2328871848.SGD","BK4585","IE00BPRC5H50.USD","LU1979443071.USD","BK0216","09969","LU2495084118.USD","161726","LU1997244956.HKD","LU1997245177.USD","BK1576","LU2242644610.SGD","BK1141","KCAI","BK4581","LU0320764599.SGD","LU2125910500.SGD","LU0348767384.USD","LU1770034418.SGD","IE00B543WZ88.USD","LU0456842615.SGD","BK4588","LU1997245094.SGD","LU0348766576.USD","LU1969619763.USD","LU1251922891.USD","LU0052750758.USD","LU2045819591.USD","IE00B5MMRT66.SGD","LU0700851271.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658673717","title":"每周股票复盘：诺诚健华（688428）科创板增发2,044,750股","url":"https://stock-news.laohu8.com/highlight/detail?id=2658673717","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658673717?lang=zh_cn&edition=full","pubTime":"2026-08-09 02:08","pubTimestamp":1786212492,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘，诺诚健华报收于29.08元，较上周的26.46元上涨9.9%。本周，诺诚健华8月7日盘中最高价报29.23元。本周关注点公司公告汇总：因2023年股权激励计划，本月科创板新增发行2,044,750股人民币普通股。公司公告汇总诺诚健华医药有限公司提交截至2026年7月31日的证券变动月报表。已发行股份总数无变化，H股普通股本月底结存1,496,284,235股，其中库存股2,486,000股。于上交所科创板上市的人民币普通股增加2,044,750股，本月底结存272,822,767股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080900000533.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","688428","BK0239","09969","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657163706","title":"8月7日诺诚健华涨6.33%，富国精准医疗混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2657163706","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657163706?lang=zh_cn&edition=full","pubTime":"2026-08-07 16:42","pubTimestamp":1786092147,"startTime":"0","endTime":"0","summary":"证券之星消息，8月7日诺诚健华涨6.33%，收盘报29.08元，换手率4.38%，成交量11.96万手，成交额3.38亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共36家，其中持有数量最多的公募基金为富国基金的富国精准医疗混合A。富国精准医疗混合A目前规模为28.98亿元，最新净值3.3622，较上一交易日上涨0.94%，近一年下跌8.02%。富国精准医疗混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700028046.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688428","09969","BK0239","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105029567","title":"诺诚健华更新2026年7月股份变动月报表，A股增发2,044,750股","url":"https://stock-news.laohu8.com/highlight/detail?id=1105029567","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105029567?lang=zh_cn&edition=full","pubTime":"2026-08-05 17:56","pubTimestamp":1785923761,"startTime":"0","endTime":"0","summary":"诺诚健华医药有限公司于2026年8月5日发布的7月股份变动月报表显示，截至2026年7月31日，公司法定注册股本仍为25,000,000,000股普通股，面值每股USD 0.000002，总额维持USD 50,000，未发生变化。在已发行股份方面，香港联交所上市的普通股数量保持不变，期末为1,493,798,235股，同时库藏股为2,486,000股。于上海证券交易所科创板上市的普通股数量则由上月底的270,778,017股增至272,822,767股，单月新增2,044,750股。该等股份增发主要源于公司执行2023年人民币股股份激励计划。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657141565","title":"8月5日诺诚健华涨5.80%，富国精准医疗混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2657141565","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657141565?lang=zh_cn&edition=full","pubTime":"2026-08-05 16:42","pubTimestamp":1785919325,"startTime":"0","endTime":"0","summary":"证券之星消息，8月5日诺诚健华涨5.80%，收盘报26.83元，换手率3.87%，成交量10.55万手，成交额2.82亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共36家，其中持有数量最多的公募基金为富国基金的富国精准医疗混合A。富国精准医疗混合A目前规模为28.98亿元，最新净值3.2715，较上一交易日上涨2.88%，近一年下跌9.4%。富国精准医疗混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500030228.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","688428","BK1574","09969","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657624596","title":"中国团队实现系统性红斑狼疮靶向治疗新突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2657624596","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657624596?lang=zh_cn&edition=full","pubTime":"2026-08-05 09:12","pubTimestamp":1785892372,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["09969","BK4077","BK1574","SLE","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656132496","title":"8月3日诺诚健华跌6.05%，富国精准医疗混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2656132496","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656132496?lang=zh_cn&edition=full","pubTime":"2026-08-03 16:41","pubTimestamp":1785746471,"startTime":"0","endTime":"0","summary":"证券之星消息，8月3日诺诚健华跌6.05%，收盘报24.86元，换手率4.51%，成交量12.3万手，成交额3.12亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共36家，其中持有数量最多的公募基金为富国基金的富国精准医疗混合A。富国精准医疗混合A目前规模为28.98亿元，最新净值3.2976，较上一交易日上涨1.82%，近一年下跌8.45%。富国精准医疗混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080300021613.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09969","688428","BK1574","BK1161","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656316514","title":"每周股票复盘：诺诚健华（688428）ICP-488治疗银屑病Ⅲ期达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2656316514","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656316514?lang=zh_cn&edition=full","pubTime":"2026-08-02 01:42","pubTimestamp":1785606134,"startTime":"0","endTime":"0","summary":"截至2026年7月31日收盘，诺诚健华报收于26.46元，较上周的27.68元下跌4.41%。本周，诺诚健华7月27日盘中最高价报28.63元。7月30日盘中最低价报25.3元。诺诚健华当前最新总市值468.11亿元，在化学制药板块市值排名10/149，在两市A股市值排名408/5202。公司将推进后续注册申报工作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080200000317.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688428","BK1574","BK0239","09969","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655824162","title":"7月30日诺诚健华跌5.72%，富国精准医疗混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2655824162","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655824162?lang=zh_cn&edition=full","pubTime":"2026-07-30 16:42","pubTimestamp":1785400974,"startTime":"0","endTime":"0","summary":"证券之星消息，7月30日诺诚健华跌5.72%，收盘报25.86元，换手率4.32%，成交量11.8万手，成交额3.11亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共36家，其中持有数量最多的公募基金为富国基金的富国精准医疗混合A。富国精准医疗混合A目前规模为28.98亿元，最新净值3.3851，较上一交易日下跌1.02%，近一年下跌6.77%。富国精准医疗混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073000026016.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09969","BK0239","688428","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654016360","title":"诺诚健华(09969.HK)：fadeucravacitinib (ICP-488)治疗中重度斑块状银屑病的 III期注册性试验成功达到其主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2654016360","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654016360?lang=zh_cn&edition=full","pubTime":"2026-07-27 17:35","pubTimestamp":1785144940,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","BK1574","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654169740","title":"诺诚健华：ICP-488治疗银屑病III期试验达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2654169740","media":"南方财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654169740?lang=zh_cn&edition=full","pubTime":"2026-07-27 17:34","pubTimestamp":1785144840,"startTime":"0","endTime":"0","summary":"南财智讯7月27日电，诺诚健华（09969.HK）发布自愿公告，公司自主研发的TYK2变构抑制剂fadeucravacinib（ICP-488）用于治疗中重度斑块状银屑病的III期注册性临床试验成功达到主要终点，统计学显著且具临床意义，并同步达成多项次要终点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607273822201140.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607273822201140.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","BK1161","BK4134","688428","BK0239","III","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653737746","title":"BMS的留白，诺诚健华的窗口","url":"https://stock-news.laohu8.com/highlight/detail?id=2653737746","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653737746?lang=zh_cn&edition=full","pubTime":"2026-07-22 15:36","pubTimestamp":1784705799,"startTime":"0","endTime":"0","summary":"更关键的产业意义在于：全球第一个用于特应性皮炎的TYK2抑制剂，大概率将出自诺诚健华之手。BMS的留白，诺诚健华的窗口全球TYK2先驱BMS的Deucravacitinib选择了另一条路：聚焦银屑病、银屑病关节炎、系统性红斑狼疮，未大规模开展针对特应性皮炎的关键注册临床。BMS这一战略留白，恰好让出了一道窄门。在特应性皮炎这条BMS放弃的赛道上，诺诚健华的坚持正在得到回报。全球权益的含金量一个值得注意的事实是，诺诚健华至今仍持有ICP-332的全部全球权益。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1784604125251670229","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["688428","BMS","BK0239","09969","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145405224","title":"港股直击 | 生物医药股走强，康方生物涨近7%，荣昌生物涨超4%，泰格医药、诺诚健华涨近3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1145405224","media":"老虎资讯综合","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145405224?lang=zh_cn&edition=full","pubTime":"2026-07-22 10:11","pubTimestamp":1784686287,"startTime":"0","endTime":"0","summary":"7月22日，港股生物医药股走强，康方生物涨近7%，荣昌生物涨超4%，泰格医药、诺诚健华涨近3%，复宏汉霖、药明康德、君实生物涨超2%。消息面上，美国总统特朗普当地时间7月21日在社交媒体发文表示，自2026.8.1起，所有进口到美国的仿制药将在未来两年内继续适用零关税。两年期满后，相关产品将被征收100%的关税，期限为一年。此后，关税将进一步提高至200%。","market":"hk","thumbnail":"https://static.tigerbbs.com/abf9f2b56caccf2c92db82642df48d35","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/abf9f2b56caccf2c92db82642df48d35"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"港股直击 | 生物医药股走强，康方生物涨近7%，荣昌生物涨超4%，泰格医药、诺诚健华涨近3%","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01877","02696","02359","09926","09995","09969","03347"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160890587","title":"诺诚健华三位高管完成31.88万股A股减持 兑现资金约902.07万元","url":"https://stock-news.laohu8.com/highlight/detail?id=1160890587","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160890587?lang=zh_cn&edition=full","pubTime":"2026-07-20 18:40","pubTimestamp":1784544049,"startTime":"0","endTime":"0","summary":"2026年7月21日，诺诚健华医药有限公司公告，公司董事及高级管理人员已按照既定计划完成A股股份减持，累计减持318,750股，占公司当前总股本的0.0180%。此次减持均通过集中竞价方式于2026年7月17日完成，合计套现约902.07万元。截至公告披露日，三位高管的减持计划已实施完毕，后续如有新的股份变动，公司将按规定及时履行信息披露义务。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09969"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"https://cn.innocarepharma.com","stockEarnings":[{"period":"1week","weight":0.0448},{"period":"1month","weight":0.0095},{"period":"3month","weight":0.2},{"period":"6month","weight":0.1801},{"period":"1year","weight":-0.1885},{"period":"ytd","weight":0.2146}],"compareEarnings":[{"period":"1week","weight":-0.0215},{"period":"1month","weight":0.0177},{"period":"3month","weight":-0.0326},{"period":"6month","weight":-0.0546},{"period":"1year","weight":-0.0158},{"period":"ytd","weight":-0.02}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"诺诚健华医药有限公司是一家主要从事生物医药研发、生产和商业化的中国公司。该公司专注于肿瘤和自身免疫性疾病等存在未满足临床需求的领域。该公司的主要产品管线包括奥布替尼、Tafasitamab、ICP-490、ICP-B02、ICP-248、ICP-B05、ICP-332、ICP-488、ICP-192、ICP-723、ICP-033和ICP-189等。其产品主要用于治疗血液瘤、实体瘤和自身免疫疾病。该公司还在开发用于治疗由T细胞功能异常所导致的自身免疫性疾病的产品。该公司在国内和国外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.166667,"avgChangeRate":-0.103999},{"month":2,"riseRate":0.666667,"avgChangeRate":0.128923},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.010195},{"month":4,"riseRate":0.714286,"avgChangeRate":0.102464},{"month":5,"riseRate":0.142857,"avgChangeRate":-0.059233},{"month":6,"riseRate":0.857143,"avgChangeRate":0.113731},{"month":7,"riseRate":0.571429,"avgChangeRate":0.05509},{"month":8,"riseRate":0.285714,"avgChangeRate":-0.056763},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.024907},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.033299},{"month":11,"riseRate":0.833333,"avgChangeRate":0.100833},{"month":12,"riseRate":0.5,"avgChangeRate":-0.012645}],"exchange":"SEHK","name":"诺诚健华","nameEN":"INNOCARE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺诚健华(09969)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺诚健华(09969)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺诚健华,09969,诺诚健华股票,诺诚健华股票老虎,诺诚健华股票老虎国际,诺诚健华行情,诺诚健华股票行情,诺诚健华股价,诺诚健华股市,诺诚健华股票价格,诺诚健华股票交易,诺诚健华股票购买,诺诚健华股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺诚健华(09969)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺诚健华(09969)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}